NCT07044960View on ClinicalTrials.gov

A Phase 1 Study of KHN702 Tablets in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 21, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Healthy
Interventions
DRUG

KHN702 tablet or placebo

Subject will receive a single KHN702 tablet or matching placebo orally in fasted state.

DRUG

KHN702 tablet or placebo

All participants will receive KHN702 tablet or matching placebo orally once a day for 7 days in fasted state.

Sponsors
All Listed Sponsors
lead

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT07044960 - A Phase 1 Study of KHN702 Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter